Gingerol-rich extract derived from Zingiber officinale Roscoe (ZOGE) is clinically effective against motion sickness (MS), yet its mechanism remains unknown. Here, we demonstrate that ZOGE confers protection by modulating a specific gut-brain immune-neuroendocrine pathway....
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is a preclinical animal study; ginger extract cannot yet be recommended as a clinical intervention for motion sickness based on this evidence alone.
Identifying a gut-based signaling pathway behind motion sickness opens a potential new drug target, which is tangentially relevant to audiologists managing vestibular patients who experience motion sickness.
- 01Gingerol-rich ginger extract reduced motion sickness in a preclinical (animal) model.
- 02The mechanism involves blocking the IL-33/ST2/PLC-γ1/TRPA1 signaling pathway in the ileum (small intestine).
- 03Findings are limited to animal models; human trials have not been conducted.
- 04Offers a potential new pathway for pharmaceutical targeting of motion sickness.
Gingerol-rich ginger extract alleviates motion sickness by inhibiting the ileal IL-33/ST2/PLC-γ1/TRPA1 signaling pathway.
studypartially supported- PMID
- 42511471
- DOI
- 10.3390/ijms27146124.
- Journal
- International Journal of Molecular Sciences
- Publication type
- research_article
- Evidence level
- 4
- Population
- Preclinical animal model of motion sickness
- Intervention
- Gingerol-rich Zingiber officinale (ginger) extract
- Comparator
- Control (untreated) animals
Primary outcomes
Motion sickness symptom severity; Ileal IL-33/ST2/PLC-γ1/TRPA1 pathway activity